Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17138274 | 1.00 | L3MBTL1 (0.45) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL17138261 | 0.76 | L3MBTL1 (0.51) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL17138280 | 0.74 | SLC18A3 (0.48) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL17138281 | 0.74 | SLC18A3 (0.48) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL28078110 | 0.72 | ADRA2B (0.56) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL17138279 | 0.72 | L3MBTL1 (0.44) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL4150592 | 0.70 | ADRA2B (0.50) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL9470012 | 0.69 | ADRA2B (0.53) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL25970514 | 0.69 | L3MBTL1 (0.44) | L3MBTL1SLC18A3ADRA2BADRA2CSLC6A2 | |
| SCHEMBL24323135 | 0.68 | ADRA2B (0.51) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2015154029-A1 | POTENT AND EFFICIENT CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | ACES Pharma Inc. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154029-A1 | POTENT AND EFFICIENT CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | ACES Pharma Inc. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | L3MBTL1 261/4885SLC18A3 3196/4885ADRA2B 4665/4885 |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | L3MBTL1 261/4885SLC18A3 3196/4885ADRA2B 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.